Table 2.
Characteristics and outcome of patients diagnosed with SARS-CoV-2 infection during admission in the HAH unit
| Patient | 1 | 2 | 3 | 4 |
|---|---|---|---|---|
| Sex | Female | Male | Female | Female |
| Age (years) | 47 | 73 | 40 | 79 |
| Diagnosis | AML | AML | Hodgkin lymphoma | MM |
| HAH program | AML consolidation treatment | AML consolidation treatment | Clinical monitoring after allo-HSCT | At-home Bortezomib |
| Admission in HAH unit (date) | 26-03-2020 | 24-03-2020 | 20-03-2020 | 07-09-2020 |
| Days in HAH unit | 3 | 10 | 18 | 18 |
| Number of visits from HAH unit | 1 | 6 | 6 | 4 |
| COVID-19 diagnosis (date) | 29-03-2020 | 03-04-2020 | 07-04-2020 | 25-09-2020 |
| Symptoms and signs | Fever, cough and rhinorrhoea | Fever and cough | Fever and cough | Fever, cough and dyspnea |
| Pneumonia | Yes | Yes | Yes | Yes |
| Treatment | Lopinavir/ritonavir + HQ/GCs/tocilizumab | HQ/GCs/tocilizumab | HQ/GCs/tocilizumab/Anakinra/HI Plasma | GCs/Remdesivir/Tocilizumab |
| ICU admission | Yes | No | Yes | No |
| Resolution | Yes | Yes | No | Yes |
allo-HSCT allogeneic hematopoietic stem cell transplantation, AML acute myeloid leukemia, COVID-19 coronavirus-19 disease, GCs glucocorticoids, HAH hospital at home, HI hyperimmune, HQ hydroxychloroquine, ICU intensive care unit, MM multiple myeloma